Nasus Pharma
NSRX
10 hedge funds and large institutions have $7.53M invested in Nasus Pharma in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
56% more capital invested
Capital invested by funds: $4.83M → $7.53M (+$2.7M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
11% more funds holding
Funds holding: 9 → 10 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.2% less ownership
Funds ownership: 18.57% → 18.36% (-0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$64.5K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$48.7K |
| 3 |
CCC
Cable Car Capital
San Francisco,
California
|
+$41.3K |
| 4 |
Renaissance Technologies
New York
|
+$35.7K |
| 5 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
-$102K |
| 2 |
HF
HRT Financial
New York
|
-$86K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.87K |
| 4 |
Morgan Stanley
New York
|
-$2.93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Balyasny Asset Management
Chicago,
Illinois
| $3.14M | – | – | – |
|
|
CCC
2
Cable Car Capital
San Francisco,
California
| $2.16M | +$41.3K | +14,083 | +2% |
|
|
VCIM
3
Velan Capital Investment Management
Alpharetta,
Georgia
| $1.26M | – | – | – |
|
4
Hudson Bay Capital Management
Stamford,
Connecticut
| $472K | – | – | – |
|
|
BL
5
Bleichroeder LP
New York
| $314K | – | – | – |
|
|
6
Citadel Advisors
Miami,
Florida
| $77K | +$64.5K | +22,004 | New |
|
|
XT
7
XTX Topco
George Town,
Cayman Islands
| $58.2K | +$48.7K | +16,640 | New |
|
|
8
Renaissance Technologies
New York
| $42.7K | +$35.7K | +12,200 | New |
|
|
9
Morgan Stanley
New York
| $3.5K | -$2.93K | -1,000 | -50% |
|
|
CIAM
10
Caitong International Asset Management
Hong Kong
| $14 | +$12 | +4 | New |
|
|
EAM
11
Empery Asset Management
New York
| – | -$102K | -45,803 | Closed |
|
|
HF
12
HRT Financial
New York
| – | -$86K | -38,897 | Closed |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$6.87K | -3,094 | Closed |
|
NSRX Hedge Fund Activity: Q2 2026 in Review
10 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Nasus Pharma (NSRX) for Q2 2026, worth a combined $7.53M — up 56% from $4.83M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NSRX positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $64.5K. The largest seller was Empery Asset Management, exiting entirely with an estimated $102K sold.
- 10 institutional investors held Nasus Pharma (NSRX) as of Q2 2026, up from 9 in Q1 2026.
- Funds reported $7.53M of Nasus Pharma stock for Q2 2026, up 56% quarter-over-quarter.
- 4 funds opened new Nasus Pharma positions in Q2 2026 and 3 closed out, a net change of +1 holder.
- The largest Nasus Pharma buyer in Q2 2026 was Citadel Advisors, an estimated $64.5K added.
- The largest Nasus Pharma seller in Q2 2026 was Empery Asset Management, an estimated $102K sold.
Based on aggregated 13F filings for Q2 2026.